Premium
A synthetic hemoregulatory peptide (HP5B) inhibits human myelopoietic colony formation (CFU‐GM) but not leukocyte phagocytosis in vitro
Author(s) -
Laerum Ole Didrik,
Sletvold Olav,
Bjerknes Robert,
Paukovits Walter R.
Publication year - 1987
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1987.tb00767.x
Subject(s) - phagocytosis , zymosan , granulocyte , in vitro , chemotaxis , flow cytometry , peptide , haematopoiesis , cfu gm , inhibitory postsynaptic potential , staphylococcus aureus , microbiology and biotechnology , biology , bone marrow , chemistry , biochemistry , immunology , stem cell , bacteria , endocrinology , receptor , genetics
A synthetic analog of a hemoregulatory peptide associated with mature human granulocyte (HP5B) has been investigated for inhibitory effects on human myelopoietic stem cells in vitro. In addition, it has been tested for effects on phagocytosis by human granulocytes and monocytes by use of an automatic flow cytometric method. A dose‐dependent inhibition of colony formation was found after preincubation of bone marrow cells for 1 h at 37°C in the range 10 −7 ‐10 −11 mol/l. Above or below these concentrations, no inhibitory effects were seen. The degree of inhibition varied from experiment to experiment, indicating variable responsiveness of the donor cells. Maximal effect was of magnitude 90% inhibition, and the optimal dose was 10 −7 mol/l. The peptide had no effect on the kinetics of phagocytosis by measurements of the uptake of fluorescent Zymosan particles or Staphylococcus aureus. This may indicate a selective effect on the precursor cells, with no effect on the functional state of their progeny, the granulocytes and monocytes.